» Articles » PMID: 17898565

T-cell Therapy After Hematopoietic Stem Cell Transplantation

Overview
Specialty Hematology
Date 2007 Sep 28
PMID 17898565
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: The separation of graft versus host disease from graft versus leukaemia reactivity and the reconstitution of immunity to infectious agents are the main goals of T-cell therapy after allogeneic hematopoietic stem cell transplantation. We describe how an improved understanding of T-cell mediated graft versus leukemia and of antiviral responses is providing effective approaches to T-cell immunotherapy.

Recent Findings: Over the past several years, researchers have developed strategies to eliminate alloreactive T cells from the graft, to expand naturally occurring regulatory T cells, and to select and expand antigen-specific T cells specific for tumor-associated or viral antigens. Incorporation of suicide genes allows the selective destruction of allodepleted or antigen-selected cells after infusion, further increasing the safety and potential applicability of these approaches.

Summary: In this review we describe current strategies for adoptive T-cell immunotherapy after hematopoietic stem cell transplantation.

Citing Articles

New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.

Chang X, Zang X, Xia C Bone Marrow Transplant. 2015; 51(3):324-32.

PMID: 26595077 DOI: 10.1038/bmt.2015.288.


Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.

Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini M Leukemia. 2014; 29(2):396-405.

PMID: 24897508 DOI: 10.1038/leu.2014.180.


Enhanced transduction and replication of RGD-fiber modified adenovirus in primary T cells.

Sengupta S, Ulasov I, Thaci B, Ahmed A, Lesniak M PLoS One. 2011; 6(3):e18091.

PMID: 21464908 PMC: 3065494. DOI: 10.1371/journal.pone.0018091.


T-cell-based therapies for malignancy and infection in childhood.

Ahmed N, Heslop H, Mackall C Pediatr Clin North Am. 2010; 57(1):83-96.

PMID: 20307713 PMC: 2844874. DOI: 10.1016/j.pcl.2009.11.002.


Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.

Klebanoff C, Yu Z, Hwang L, Palmer D, Gattinoni L, Restifo N Blood. 2009; 114(9):1776-83.

PMID: 19561320 PMC: 2738567. DOI: 10.1182/blood-2008-12-192419.